1. Home
  2. HZO vs ABUS Comparison

HZO vs ABUS Comparison

Compare HZO & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MarineMax Inc.  (FL)

HZO

MarineMax Inc. (FL)

HOLD

Current Price

$52.11

Market Cap

788.1M

ML Signal

HOLD

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

HOLD

Current Price

$5.21

Market Cap

839.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HZO
ABUS
Founded
1998
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Auto & Home Supply Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
788.1M
839.5M
IPO Year
1998
2008

Fundamental Metrics

Financial Performance
Metric
HZO
ABUS
Price
$52.11
$5.21
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
1
Target Price
$30.00
$5.00
AVG Volume (30 Days)
815.8K
2.1M
Earning Date
04-23-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
55.26
EPS
0.21
0.84
Revenue
$2,309,288,000.00
$14,083,000.00
Revenue This Year
$3.67
N/A
Revenue Next Year
$4.01
$239.71
P/E Ratio
$248.57
$6.19
Revenue Growth
N/A
128.21
52 Week Low
$21.42
$3.50
52 Week High
$52.46
$5.45

Technical Indicators

Market Signals
Indicator
HZO
ABUS
Relative Strength Index (RSI) 81.04 66.79
Support Level $31.96 $4.15
Resistance Level $52.46 $5.38
Average True Range (ATR) 0.60 0.19
MACD 0.54 0.07
Stochastic Oscillator 98.26 74.76

Price Performance

Historical Comparison
HZO
ABUS

About HZO MarineMax Inc. (FL)

MarineMax Inc is a United-States-based company that sells new and used recreational boats under premium brands, and related marine products, like engines, parts, and accessories. The company is also engaged in other businesses, including providing services of repair, maintenance, and storage; managing related boat financing, insurance, and others; offering brokerage sales of boats and yachts; and operating a yacht charter business. The reportable segments of the company are Retail Operations and Product Manufacturing. The Retail Operations segment generates the majority of the company's revenue. The sale of new and used boats accounts for the majority of the company's total revenue. It serves customers across the U.S and international market.

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Share on Social Networks: